Biotech companies struggle to detect and manage safety signals in cell therapy trials before patient deaths occur

Biotech firms running cell therapy programs face critical delays in identifying adverse events and safety signals, leading to preventable patient deaths and program shutdowns. Current monitoring systems fail to correlate drug preparation protocols with therapy outcomes, forcing companies to attribute deaths only after fatalities occur. This lack of real-time safety data integration causes loss of investor confidence, regulatory rejection, and complete program termination.